

PATENT

ATTORNEY DOCKET NO. VEOC.001.01US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Geuze and Melief

) Examiner: Amy DeCloux

Serial No.: 09/011,167

)
) Art Unit: 1644

Filed: October 5, 1998

)
)

For: CELL DERIVED ANTIGEN PRESENTING
VESICLES

) **VERSION WITH MARKINGS TO**
) **SHOW CHANGES MADE TO THE**
) **CLAIMS**

BOX AF

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

These marked-up versions of the claims accompany the attached Amendment for the above identified patent application, and are submitted with the Appellant's Brief on Appeal pursuant to 37 CFR § 1.192.

IN THE CLAIMS:

Cancel Claim 2.

3. (Reiterated) The antigen presenting vesicle according to claim 13 further comprising at least partially processed antigens.

4. (Reiterated) The vesicle according to claim 3 wherein said at least partially processed antigens are presented in the context of MHC class I proteins.

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this paper or fee is being deposited with the United States Postal Service as first class mail in an envelope addressed to BOX AF, Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231
on November 19, 2001

Signature: _____

Printed Name: Jeffrey M. Libby

6. (Reiterated) The antigen presenting vesicle according to claim 13, wherein said antigen presenting cell is derived from a B-lymphocyte, a Langerhans cell, a macrophage or a dendritic cell.

9. (Three Times Amended) [A method for obtaining antigen presenting vesicles] An antigen presenting vesicle having a membrane and a major histocompatibility complex (MHC) class I protein, [said method comprising] obtained by the step of:

recovering a membrane-enriched fraction obtained by differential centrifugation of membrane-containing fractions of cell culture supernatants or lysates of antigen presenting cells [whereby fractions containing said antigen presenting vesicles are obtained].

Cancel Claim 10.

11. (Amended) [A method for obtaining antigen presenting vesicles] An antigen presenting vesicle having a membrane and a major histocompatibility complex [(MHC) protein derived from MHC] class II I molecule, [said method comprising] obtained by the step of:

recovering a 70,000 x g pellet obtained by differential centrifugation of membrane-containing fractions of cell culture media or lysates of antigen presenting cells containing MHC class II, whereby fractions containing said antigen presenting vesicles are obtained].

12. (Amended) A [method for obtaining] purified antigen presenting vesicle[s] having a membrane and a major histocompatibility complex [(MHC) protein derived from MHC] class II I molecule, [said method comprising] obtained by the step of:

recovering a fraction having a buoyant density of 1.10 to 1.22 g/ml from a 70,000 x g pellet obtained by differential centrifugation of membrane-containing fractions of cell culture supernatants or lysates of antigen presenting cells containing MHC class II, whereby purified antigen presenting vesicles are obtained].

13. (Twice Amended) An antigen presenting vesicle free from its natural surroundings, comprising:


a membrane and a major histocompatibility complex (MHC) class I protein or a functional derivative or fragment thereof, wherein said antigen presenting vesicle is obtainable from [a] an antigen presenting cell.

CONCLUSION

Should the Board of Appeals have any questions regarding the above, the Board is invited to call the undersigned.

Respectfully submitted,

Dated: November 19, 2001



Jeffrey M. Libby, Ph.D.
Reg. No. 48,251

Rae-Venter Law Group, P.C.
P. O. Box 60039
Palo Alto, CA 94306
Telephone: (415) 328-4400
Facsimile: (415) 328-4477

BRV/JML/jml

VEOC.001.01US.VersionMarkings.091901.doc